NEW YORK, August 9, 2016 /PRNewswire/ --
With the U.S. election fast approaching, some investors cannot help but question the outcome's probable impact on the Healthcare sector. A post-election scenario may lead to potential drug-price reductions and amended policies. This morning, Stock-Callers.com issued research reports on four major companies in the Drug Manufacturers industry, namely: Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Merck & Co. Inc. (NYSE: MRK), and Johnson & Johnson (NYSE: JNJ). Learn more about these stocks by downloading their free research reports in PDF format at:
On Monday, shares in Pfizer Inc. recorded a trading volume of 30.47 million shares, which was above their three months average volume of 23.82 million shares. The stock ended the day at $34.93, which was a drop of 1.44%. The Company's shares have gained 5.07% over the previous three months and 11.19% since the start of this year. The stock is trading above its 200-day moving average by 8.55%. Furthermore, shares of Pfizer, which discovers, develops, manufactures, and sells healthcare products worldwide, have a Relative Strength Index (RSI) of 37.67.
On August 8th, 2016, Pfizer announced the publication of a new post-hoc analysis of data from three studies of VYNDAQEL in patients with mild transthyretin familial amyloid polyneuropathy. The analysis, showed that treatment with VYNDAQEL initiated during the early stage of the disease resulted in minimal neurological disease progression and in preservation of body weight, which often declines as the disease progresses. VYNDAQEL was well tolerated with no new safety signals observed. Sign up and read the free research report on PFE at:
North Chicago, Illinois-based AbbVie Inc.'s stock finished yesterday's session 0.30% lower at $66.34 and with a total volume of 5.29 million shares traded. The Company's shares have gained 4.31% in the last one month, 5.06% over the previous three months, and 15.25% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 5.96% and 14.07%, respectively. Furthermore, shares of AbbVie, which discovers, develops, manufactures, and sells pharmaceutical products worldwide, have an RSI of 65.20.
On July 25th, 2016, AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application for VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir and ritonavir) extended-release tablets. VIEKIRA XR is used for the treatment of patients with chronic genotype 1 hepatitis C virus infection, including those with compensated cirrhosis. The complimentary research report on ABBV can be downloaded at:
At the closing bell on Monday, shares in Kenilworth, New Jersey headquartered Merck & Co. Inc. saw a decline of 1.57%, ending the day at $62.86. The stock recorded a trading volume of 25.02 million shares, which was above its three months average volume of 9.62 million shares. The Company's shares have advanced 5.91% in the last one month, 17.14% over the previous three months, and 21.03% since the start of this year. The stock is trading 8.98% above its 50-day moving average and 17.28% above its 200-day moving average. Moreover, shares of Merck & Co., which provides health care solutions worldwide, have an RSI of 69.78.
On August 8th, 2016, Merck announced that the FDA has approved KEYTRUDA® (pembrolizumab), the company's anti-PD-1 therapy, for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy. Under the FDA's accelerated approval regulations, this indication for KEYTRUDA is approved based on tumor response rate and durability of response.
On August 08th, 2016, research firm Credit Suisse upgraded the Company's stock rating from 'Neutral' to 'Outperform', issuing a target price of $73 per share. Register for free on Stock-Callers.com and access the latest report on MRK at:
Johnson & Johnson
New Brunswick, New Jersey-based Johnson & Johnson's stock ended the day 0.47% lower at $123.65 and with a total volume of 5.22 million shares traded. The Company's shares have gained 0.65% in the last month, 9.51% over the previous three months, and 22.11% on an YTD basis. The stock is trading 3.06% above its 50-day moving average and 14.50% above its 200-day moving average. Additionally, shares of Johnson & Johnson, which together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide, have an RSI of 53.54.
On July 18th, 2016, the company announced that Johnson & Johnson Consumer Inc. has successfully completed the acquisition of Vogue International LLC, a privately-held company focused on the marketing, development and distribution of salon-influenced and nature inspired hair care and other personal care products, for $3.3 billion in cash.
On July 21st, 2016, research firm Deutsche Bank reiterated its 'Hold' rating on the Company's stock with an increase of the target price from $125 a share to $142 a share. Get free access to your research report on JNJ at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA